Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + carmustine
- Development stage
- Discontinued
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
acetaminophen + carmustine is an investigational combination chemotherapy regimen evaluated by Memorial Sloan Kettering Cancer Center for the treatment of stage III and stage IV metastatic melanoma. In this protocol, high-dose acetaminophen is administered as a chemosensitizing agent to deplete intracellular glutathione (GSH) levels. Glutathione is a primary cellular antioxidant that protects cells from oxidative stress and detoxifies certain chemotherapy drugs, including alkylating agents. By reducing GSH concentrations, acetaminophen enhances the DNA-alkylating activity and overall cytotoxicity of carmustine (BCNU) against melanoma cells. This strategy is designed to sensitize tumor cells that are otherwise resistant to nitrosourea-based chemotherapy. The regimen typically includes the administration of acetylcysteine as a rescue agent to replenish glutathione in normal tissues and mitigate potential hepatotoxicity from the high-dose acetaminophen.
- Other names
- acetaminophen + carmustineparacetamol + carmustinehigh-dose acetaminophen and carmustine
02
Targets
DNAGSH (Glutathione)
Beyond the preview
Go deeper on acetaminophen + carmustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + carmustine.